Lhasa Limited shared knowledge shared progress
Home > Library > Search the Library > Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - Recording
Publications

Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - Recording

Jones D;

Guest speaker, David Jones, Expert Pharmaco-Toxicologist at MHRA, gave this presentation as part of session 3 of Lhasa's 2020 AOP themed virtual symposium.

The session title was 'The potential utility of AOPs in the future of regulatory decision-making' and was the third in a series of 4 webinars that made up the symposium. 

This publication is a recording of David's presentation slides. 

Download

Additional Documents

    • Linked In
    • Twitter
    • Instagram
    • Facebook

    © 2022 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
    VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

    Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.